EUCTR2020-003306-32-HU进行中（未招募）1 期
Phase IV study on the feasibility of a preventative/therapeutic approach with Benzydamine Oromucosal solution in radiation-induced Oral Mucositis (OM) in patients with head and neck cancer (HNC) - BOOM study
Angelini Pharma S.p.A.0 个研究点目标入组 100 人开始时间: 2020年11月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female patients of any ethnic origin =18 years of age.
- •2. Patients diagnosed with stage III or IV HNC (histologic or cytologic diagnosis), according to VIII AJCC staging system, who are candidate and are about to start RT, with or without concomitant CT, with curative intent, either with exclusive or postoperative intent.
- •3. Eastern Cooperative Oncology Group (ECOG) performance status with a score of 0, or 1, or 2.
- •4. Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent and the Declaration of consent for the processing of personal data.
- •5. Women of childbearing potential or with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the end of the study, using an appropriate birth control method, such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:
- •Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1. Patients with reported allergy to benzydamine or another component of the formulation used.
- •2. Any contraindications listed in the local product’s Summary of Product Characteristics (SmPCs).
- •3. Patients with prior head and neck RT (in the previous 6 months), or patients who received a palliative treatment.
- •4. Patients with distant metastatic disease and/or severe cognitive impairment and/or clinically symptomatic brain metastases and/or patients with significant comorbid conditions.
- •5. Patients with mucositis due to other medical conditions (e.g., gastro-oesophageal reflux, autoimmune disease, etc.).
- •6. Patients who use other oromucosal products (over the counter or prescription) for the same disease.
- •7. Prescription of other rinses (anaesthetics like magic mouthwashes” or others), except from sodium bicarbonate rinses.
- •8. Use of chlorhexidine, other anti-inflammatory mouthwashes solutions, misoprostol, granulocyte macrophage colony-stimulating factor (GM-CSF) and sucralfate gel.
- •9. Employment of antifungal or antibiotic drugs as prophylaxis for mucositis; any therapeutic use in case of overt clinical infections is allowed.
- •10. Patients treated with other therapies that can cause mucositis, except for the therapies for their primary condition.
- •11. Patients treated with any topical anti-inflammatory/analgesic products for the mucositis.
- •12. Any other product that can interfere with the evaluation of pain or inflammatory state, according to the Investigator’s assessment.
研究者
相似试验
进行中（未招募）
1 期
BOOM study (Benzydamine Oromucosal solution in Oral Mucositis)EUCTR2020-003306-32-PLAngelini Pharma S.p.A.100
招募中
4 期
A clinical trial to study the safety and efficacy of Pulmosil (Sildenafil Injection) for the treatment of hypertension.CTRI/2016/11/007424Sun Pharmaceutical Industries Limited
招募中
不适用
Feasibility assessment of the prophylactic Use of AneuFix at the time of EVAR implantatioEndoleakLeak10002363NL-OMON54373TripleMed B.V.5
进行中（未招募）
1 期
Study to evaluate the effectiveness of aflibercept in patients with macular edema secondary to central retinal vein occlusion.Macular edema secondary to central retinal vein occlusion.EUCTR2014-000975-21-ESFundación Retinaplus +
招募中
不适用
A study to test the advantages of ultrasound guided spinal anesthsia as compared to conventional landmark using spinal anesthesiaCTRI/2017/11/010545Armed Forces Medical College